Please try another search
Trex Wind-down, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was formerly known as Timber Pharmaceuticals, Inc. and changed its name to Trex Wind-down, Inc. in January 2024. Trex Wind-down, Inc. was founded in 2019 and is headquartered in Hampton, New Hampshire.
Name | Age | Since | Title |
---|---|---|---|
Edward J. Sitar | 61 | 2020 | Lead Independent Director |
David Eric Cohen | 59 | 2020 | Independent Director |
Gianluca Pirozzi | 46 | 2020 | Independent Director |
Lubor Gaal | 56 | 2020 | Independent Director |
John Koconis | 53 | 2020 | Chairman, CEO & President |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review